BMS Sees Zeposia As Safer Oral Option In Ulcerative Colitis
Efficacy Comparable To Gilead/Galapagos JAK Inhibitor Filgotinib
Executive Summary
Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response.
You may also be interested in...
BMS’s Plans For Zeposia In Crohn’s Dubious Following Phase III Miss
The oral S1P modulator, approved to treat ulcerative colitis and MS, missed its primary endpoint in the first of two Phase III induction studies in moderate-to-severe Crohn’s disease.
Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI
The second US approval for the S1P receptor agonist brings Bristol into the gastrointestinal space, and is just the starting point for the pharma in that arena, the company told Scrip.
Biotech’s Double-Edged Sword: Extraordinary Funding Run Contributes To Talent Crisis
Finding good leaders always has been hard, but record-breaking VC investment and IPOs, COVID-19 and diversity initiatives have compounded the growing problem.